YiChang HEC ChangJiang Pharmaceutical Co., Ltd.
YIHCF · OTC
12/31/2024 | 6/30/2024 | 12/31/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Revenue | $1 | $2 | $3 | $3 |
| % Growth | -48.3% | -20.4% | -3.8% | – |
| Cost of Goods Sold | $0 | $1 | $1 | $1 |
| Gross Profit | $1 | $2 | $2 | $3 |
| % Margin | 66.6% | 79.4% | 78.5% | 79.9% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $1 | $1 | $1 | $1 |
| Sales & Mktg Exp. | $0 | $1 | $1 | $1 |
| Other Operating Expenses | $0 | -$0 | $0 | $0 |
| Operating Expenses | $1 | $1 | $1 | $1 |
| Operating Income | -$0 | $1 | $1 | $1 |
| % Margin | -15.2% | 35.3% | 31% | 46.3% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$0 | $1 | $1 | $1 |
| Tax Expense | -$0 | $0 | $0 | $0 |
| Net Income | -$0 | $1 | $1 | $1 |
| % Margin | -15.9% | 27.9% | 31.2% | 32.1% |
| EPS | -0.23 | 0.78 | 1.09 | 1.17 |
| % Growth | -129.5% | -28.4% | -6.8% | – |
| EPS Diluted | -0.23 | 0.78 | 1.09 | 1.17 |
| Weighted Avg Shares Out | 1 | 1 | 1 | 1 |
| Weighted Avg Shares Out Dil | 1 | 1 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | -$8 | $8 | $0 | $0 |
| EBITDA | -$8 | $9 | $1 | $2 |
| % Margin | -625.4% | 366.9% | 48.6% | 51.7% |